Moomen Hassan

Moomen Hassan

Auto-generated profile, based on publicly available information

Moomen Hassan

Marmara University School of Medicine, Istanbul, Turkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
TETansu Eris
Tansu Eris
MHMoomen Hassan
Moomen Hassan
YHYousra Hikal
Yousra Hikal
ESEnas Sawah
Enas Sawah
FDFatemeh Daneshgar
Fatemeh Daneshgar
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. FibroScan® is used for follow-up of fibrosis and steatosis. This single-center study aims to review the distribution of indications by referral to FibroScan®. Materials and Methods: Demographic characteristics, CLD etiologies, and FibroScan® parameters of the patients who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated. Results: Out of 9345 patients, 4946 (52.93%) were males, and the median age was 48 [18–88] years. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N=4768, 51.02%), followed by hepatitis B (N=3194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, and CLD etiology, the results revealed that patients with older age (Odds ratio (OR)=2.908; confidence interval (CI)=2.597–3.256; p